Skip to content

Abivax

  • EN
  • FR
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
  • EN
  • FR

News & Events

Press Coverage

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019

LabioTech

January 18, 2016

A Phase II HIV Antiviral from France Has Promising Results

in-Pharma

July 6, 2015

ABIVAX’s IPO to fund HIV and hep B pipeline before potential Big Pharma deal

in-Pharma

April 14, 2015

Abivax’s ARV action could herald functional HIV cure, says firm

Drug Discovery & Development

December 1, 2014

ABIVAX Completes First-In-Man Study of HIV Treatment

BioSpace

December 1, 2014

ABIVAX successfully completes first-in-man study of ABX464, a highly differentiated small molecule targeting HIV.

  • 1
  • …
  • 44
  • 45
  • 46

References available upon request.

© 2025 All rights reserved by Abivax 07/2024 Privacy and Terms of Use
Consent Preferences
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn